Cronos Group reports Q2 EPS (10c) vs (2c) last year

Reports Q2 revenue $33.455M vs $27.762M last year. “Cronos delivered another quarter of strong performance, highlighted by record sales from Cronos Israel and continued momentum in international markets. Our strength abroad has been instrumental in driving meaningful margin improvement, underscoring the benefits of our global strategy. Our results in Israel reflect the strong demand for high-quality medical cannabis and the operational excellence of our team on the ground. Achieving a record quarter there is a testament to our ability to scale efficiently while meeting the needs of patients,” said Mike Gorenstein, Chairman, President and CEO of Cronos.